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Treatment for exercise induced asthma (EIA) in sporting competition is controlled to prevent the use of agents which 
might enhance physical performance. There is little information concerning the effects of the long-acting inhaled, 
and oral, sustained release type bronchodilators on the cardiorespiratory effects of submaximal exercise. The aim of 
this study was to compare the cardiorespiratory effects of submaximal exercise in patients with EIA before and after 
pretreatment with high-dose inhaled salmeterol xinafoate (SX) and controlled release oral salbutamol (CR). 
Patients were treated with SX (1OOpg b.d.) and CR (8 mg b.d.) for 23 days in a double-blind randomized 
cross-over design, with a 5-14 day washout period between treatments. A submaximal exercise test (total exercise 
time 6 min, final 3 min at 60% of tiEpeak) was performed prior to each treatment period, and repeated at 1, 6, and 
12 h postdose at the end of the treatment period. 
Two subjects were withdrawn from the study. Three subjects required relief medication after 1 h (CR) and one 
subject after 6 h (SX) and they did not perform further exercise tests. Both treatments increased baseline FEV,, with 
SX producing significantly greater pre-exercise bronchodilation than CR (P=O.O4). Following CR, there were no 
significant differences from the pretreatment values for FO,, t;, respiratory exchange ratio, heart rate, ventilatory 
equivalents for PO,, and oxygen pulse during the submaximal exercise challenge. Following SX, there were no 
significant differences for any of the exercise variables except for i/, at 6 and 12 h (mean increase 4.27 1 min - ’ at 6 h, 
PcO.01 and 4.69 1 min- ’ at 12 h, P=O.O5). 
The changes in ventilation following SX did not have an effect on oxygen consumption, and the ventilatory 
efficiency (~J~O,) remained unchanged. The findings from this study demonstrate that, despite exercising from a 
higher baseline FEV, , short pretreatment periods with controlled release oral salbutamol and with inhaled 
salmeterol do not confer any cardiorespiratory advantage during submaximal exercise in subjects with EIA. 
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Introduction 
There are many sportspeople who are disadvantaged as a 
result of asthma. The treatment of EIA in such individuals 
may require individualized treatment, and therefore the 
opportunity to choose from a wide variety of agents is 
important. Prolonged control of EIA is particularly desir- 
able for submaximal, endurance training schedules, and 
competition events which occur over 2-6 h. The short 
acting inhaled &agonists have been permitted in sporting 
competitions for some time, and the long-acting, inhaled 
agents have recently gained approval (1). The oral 
&agonists remain prohibited. Concern centres around any 
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enhancing effects the agents might confer on the exercise 
response leading to competitive advantage. 
We have recently demonstrated EIA inhibition over 12 h 
with the maximum dose of salmeterol (100 pug b.d.) and, 
surprisingly, protection for some patients using controlled 
release oral salbutamol (8 mg b.d.) (2). However, there is 
little information concerning the effects on exercise follow- 
ing short, pretreatment periods of either agent. The aim of 
this study was to examine the cardiorespiratory response to 
submaximal exercise following a short, pretreatment period 
with high-dose salmeterol and controlled release oral 
salbutamol in subjects with EIA. 
Methods 
STUDY DESIGN 
The design was double-blind, randomized cross-over with 
treatment periods of 3-5 days, and a washout period of 
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5-14 days between treatments. During an initial screening 
visit patients performed a maximal, incremental exercise 
test on the treadmill to measure peak ventilation ( tiEpeak), 
and to assess the fall in FEV,, postexercise. A value of 60% 
Cpeak was determined from the maximal test and used as a 
target value for all subsequent submaximal exercise chal- 
lenges. At the second visit patients performed a submaximal 
exercise test lasting 6 min, with the final 3 min at a work 
rate which related to the target value of 60% tiEpeak. 
Ventilation, gas exchange and heart rate were measured 
throughout. 
SUBJECTS 
Fourteen patients (seven men), mean (SD) age 32 (12) years 
were recruited. Only patients with a history of asthma, and 
a baseline FEV, >60% of the predicted value were included 
in the study. All the patients demonstrated >20% fall in 
FEV, postexercise during an initial screening test. All of the 
patients used inhaled, short acting &agonists as required, 
and eight patients were using regular inhaled steroids 
(<4OOpg). No patients were on oral, or long acting, 
&agonists. The group had been free from respiratory tract 
infections for more than 4 weeks prior to the study, and 
from exacerbations of asthma for a similar length of time. 
Informed consent was obtained, and the protocol was 
approved by the District Ethics Committee. 
At the end of the second visit patients were issued with 
the randomized treatment and instructed to commence the 
regimen the following morning. After a treatment period of 
2 3 days patients returned to the exercise laboratory (visit 
3) and performed three submaximal exercise tests over a 
12-h period following the administration of a dose of the 
randomized treatment. The tests were performed at 1, 6 and 
12 h postdose, and the cardiorespiratory measurements 
were recorded during each test. At the end of visit 3 a 
treatment washout phase of 5-14 days commenced. At visit 
4, patients repeated the submaximal exercise challenge, and 
were issued with their second treatment regimen. Again, 
following a treatment period of 23 days, patients per- 
formed three exercise challenges over a period of 12 h (visit 
5), in the same manner as described for visit 3. 
MEASUREMENTS 
FEV, was measured using a wedge bellows spirometer 
(Vitalograph, model R, Bucks, U.K.) before and for 30 min 
postexercise at all visits. Three technically acceptable 
measurements were made according to the BTSlARTP 
Guidelines (3) and the highest value was recorded for 
analysis. Predicted values were calculated from the 
European Guidelines (4). 
The ventilation and gas exchange were measured using a 
computerized, breath-by-breath exercise system (Oxycon 
Beta, Erich, Jaeger, U.K. Ltd). The heart rate (HR) was 
measured from a single lead ECG signal. The oxygen 
consumption (kO,), k,, respiratory exchange ratio RER 
(i/CO,lpO,), HR, oxygen pulse (0, pulse) and ventilatory 
equivalent for PO, (p,/pO,) were averaged over the final 
30 s of each exercise test for the statistical analysis. The 
ambient temperature and humidity were recorded. All 
exercise tests were performed with room temperature 
~25°C and relative humidity ~50%. 
Finger tremor was recorded prior to each exercise test 
(except visit l), and before and 15 min after the treatment 
dose at visits 3 and 5. The measurements were made 
according to the method described by Birmingham (5). 
Briefly, a small accelerometer (model 4367, Bruel and 
Kjaer, Denmark) was secured to the middle finger of 
the dominant hand, and measurements of acceleration 
recorded onto magnetic tape for 1 min. The forearm 
was supported and the hand extended. Digital spectral 
analysis of the tapes was performed by a dedicated com- 
puter programme in the Department of Physiology and 
Pharmacology, Queens Medical Centre, Nottingham. 
DOSAGE REGIMEN AND SAFETY 
The dosing regimen was salbutamol controlled release 
capsules (CR) 8 mg b.d. and salmeterol xinafoate (SX) 
1OOpg b.d. via MDI. Correct inhaler technique was ensured 
prior to the start of treatment. Relief medication during the 
treatment periods was salbutamol MD1 (100 pug). All other 
asthma medications remained the same. 
Resting blood pressure and a 12-lead ECG were per- 
formed during the screening visit to ensure there were no 
cardiovascular contra-indications to exercise. A single lead 
ECG was also monitored throughout the exercise tests. If 
there was a persistent fall in the FEV, of >30% postexer- 
cise, relief medication was administered for safety reasons 
and for patient comfort, and also at any other time if 
requested by the patient. Patients were not allowed to leave 
the laboratory until the FEV, had returned to 90% of the 
baseline value. All adverse events throughout the study 
period were documented. 
STATISTICAL ANALYSIS 
The end exercise values for pB, PO,, RER, HR, 0, pulse 
and ?Ji/O, from each of the exercise tests during the 
treatment phases (at 1, 6, and 12 h) were compared to the 
corresponding pretreatment measurements using analysis 
of variance (ANOVA). Within- and between-treatment 
differences at each of the time points were also compared 
using ANOVA. Changes in the pre-exercise FEV, were 
compared using repeated measures analysis to investigate 
differences in the profile of the FEV, measurement. The % 
fall in FEV, at each of the time points were compared 
between treatments using the Wilcoxon rank sum test. The 
change in finger tremor from pretreatment levels, for both 
dominant frequency and peak frequency band root mean 
square of tremor amplitude (PFB RMS), was compared 
between treatments using an ANOVA. Carry-over and 
treatment-by-period interaction were judged at the 10% 
level of significance, whilst all other effects were judged at 
the 5% level. 
TABLE 1. Pre-exercise FEV, and % fall postexercise 





Post-ex Pre-ex Post-ex 
% fall FEV, % fall 
Pretreatment (i.e. visit 2 or 4) 3.17 33 3.16 29 
Treatment phase 
1 h postdose 3.69 7 3.43 22 
6 h postdose 3.75 9 3.61 22 
12 h postdose 3.57 17 3.32 22 
Adjusted mean FEV, (1) pre- and post-treatment prior to each exercise challenge, and median % fall 
in FEV, postexercise. 
TABLE 2. Cardiorespiratory response to submaximal exercise 
Treatment 
PO, 




beat min - ’ 
0, pulse 
ml beat - ’ i/J PO, 
SX 
Pre-R, (visit 2 or 4) 31.3 (1.3) 74.2 (2.5) 1.09 (0.05) 157 (7) 14.8 (0.4) 31.3 (0.8) 
Postdose 1 31.6 (1.0) 77.8 (2.2) 1.11 (0.05) 158 (1) 14.9 (0.5) 31.7 (1.2) 
time (h) 6 3 1.4 (0.4) 78.4 (1.2)** 1.13 (0.05) 159 (1) 14.9 (0.2) 32.5 (0.7) 
12 30.6 (0.8) 78.8 (2.3)* 1.12 (0.06) 159 (1) 14.3 (0.2) 32.7 (0.9) 
CR 
Pre-R, (visit 2 or 4) 32.3 (1.3) 77.3 (2.5) 1.07 (0.06) 150 (7) 15.4 (0.4) 30.5 (0.8) 
Post dose 1 30.9 (1.1) 73.9 (2.2) 1.06 (0.04) 156 (1) 15.1 (0.5) 30.6 (1.2) 
time (h) 6 30.6 (0.5) 75.6 (1.6) 1.05 (0.05) 160 (2) 14.6 (0.3) 31.2 (0.8) 
12 29.8 (0.8) 74.3 (2.6) 1.05 (0.06) 159 (2) 14.2 (0.2) 31.4 (1.0) 
Pre- (visit 2 or 4) and post-treatment mean (SE) values of oxygen consumption (PO,), ventilation (VJ, respiratory exchange 
ratio (RER), heart rate (HR), oxygen pulse (0, pulse) and ventilatory equivalents for oxygen (VJPO,) during repeated 
submaximal exercise challenge. 
Results 
Two patients were withdrawn from the study. One patient 
had severe tremor during the first treatment period (group 
1, active treatment CR), and one patient was withdrawn 
due to an unstable baseline FEV, during the washout phase 
between treatments (> 10% difference from the baseline 
measurement at visit 2). The results are presented for the 
remaining 12 patients. 
One patient requested relief medication for wheeze and a 
tight chest after falling asleep between the 6 and 12 h 
exercise challenges on the SX challenge day. During the CR 
challenge day relief medication was administered to three 
patients for a persistent fall in FEV, (>30%) at 1 h. No 
further exercise tests were carried out following the admin- 
istration of relief medication. 
greater pre-exercise bronchodilation than CR (P=O.O4). 
There were no significant differences between treatments for 
the % fall in FEV,, however, the median % fall following 
CR was larger and just failed to reach significance at 6 h 
(PzO.07). Following SX, the fall in postexercise FEV, was 
attenuated (~20%) in eight patients for 6 h, and in six 
patients the inhibition persisted for 12 h. Following CR, the 
fall in FEV, was attenuated for 12 h in five patients (42% of 
the group). The postexercise fall in FEV, was inhibited by 
SX and not CR for three patients at all time points, whilst 
for two patients the fall in FEV, was inhibited by CR and 
not SX at all time points. 
CARDIORESPIRATORY RESPONSE TO 
SUBMAXIMAL EXERCISE 
The mean % predicted FEV, was 93 (20) % at the A summary of the cardiorespiratory data from each of the 
baseline (screening) visit. The mean FEV, values prior to treatment phases is shown in Table 2. During the SX 
each treatment phase (visits 2 and 4), and prior to each treatment phase the pE during the exercise test at 6 h was 
exercise challenge are shown in Table 1. The median % falls significantly higher than the pretreatment value [mean (SE) 
postexercise are also given. SX produced significantly increase 4.27 (1.22) 1 min - ‘, P<O.Ol] and at 12 h it was of 
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FIG. 1. Mean and 95% confidence intervals for the differences between the pretreatment and post-treatment values of 
oxygen consumption (PO,), ventilation (PJ and heart rate (HR) during submaximal exercise. 
borderline significance [4.69 (1.93) 1 min - ‘, P= 0.051. With 
the exception of these two values there were no other 
significant differences between the pre- and posttreatment 
values for PO,, t;, RER, HR, 0, pulse and t-,/PO, for 
either treatment. In addition there were no significant 
differences between each time point within the same treat- 
ment phase. There was a tendency for a more variable heart 
rate response to exercise during the CR treatment phase. 
There were no significant carry-over or treatment-by-period 
interactions detected. The mean differences and 95% confi- 
dence intervals, between pretreatment and each of the 
exercise time points for kE, PO, and HR are illustrated 
in Fig. 1. 
FINGER TREMOR AND OTHER SIDE-EFFECTS 
There was no significant change in the dominant frequency 
of the finger tremor with either treatment. However, both 
treatments increased the amplitude of finger tremor 
above the pretreatment values, with CR having the greater 
effect (Fig. 2). The greatest differences between treatments 
were at 15 min, 1 and 12 h postdosing (P values 0.09, 0.09 
and 0.01, respectively). After the ‘chronic’ dosing period 
a single dose of either drug did not have an additional 
‘acute’ effect. 
Finger and general tremor were reported symptoms 
during both treatments, with slightly fewer patients noticing 
the symptom with SX (six reports with SX, and eight 
reports with CR). However, more patients reported palpi- 
tations, during the SX treatment period (n=3) compared 
to the CR treatment (n=l). Equal numbers of patients 
reported at least one incidence of headache (n=4 for both 
SX and CR). 
Discussion 
Individuals with EIA are at a disadvantage in performing 
exercise, and selected inhaled &agonists are allowed for 
use in sports to enable asthmatics to compete on equal 
levels with healthy individuals. However, treatment should 
act to minimize the EIA and not augment athletic perform- 
ance and therefore is permitted where there is evidence that 
asthmatics do not derive additional ergogenic benefit (6). In 
this study we examined the cardiorespiratory response to 
submaximal exercise following a short period of premedi- 
cation with high-dose salmeterol and controlled release oral 
salbutamol, and, to our knowledge, these conditions have 
not been examined previously. Although the study was 
limited, it was tightly controlled in terms of patient 
T 







FIG. 2. Mean (SE) increase in finger tremor (m s -2) from 
pretreatment levels. (a), SX; (B), CR. *P=O.Ol c.f. SX. 
selection, stability of disease and repetition of exercise 
challenge. There was repeated performance of the submaxi- 
mal exercise challenge over the time course of the study 
(mean duration 24 days, range 18-37 days) with no evi- 
dence of a treatment effect on the oxygen cost, or the heart 
rate response to the exertion. These results suggest any 
systemic effects did not interfere with the cardiorespiratory 
response to exercise. 
There was an increase in the ventilatory response follow- 
ing the high-dose SX at the 6 and 12 h time points. Studies 
with short duration p-agonists have demonstrated changes 
in ventilationperfusion relationships, effects on the respir- 
atory drive (7), on cardiac output and tissue perfusion 
leading to cardiodynamic hyperpnoea (8), and increased 
lactate accumulation during exercise (9). In a study which 
compared salmeterol and inhaled salbutamol, blood lactate 
levels were significantly higher with salbutamol after 15 min 
of exercise, which the authors suggested may be related to 
alterations in the balance between carbohydrate and lipid 
metabolism induced by salbutamol (9). Although the blood 
lactate concentration was not measured in the present 
study, the respiratory exchange ratio, which reflects tissue 
metabolic activity and body stores of respiratory gases, was 
not significantly different between pre- and posttreatment 
periods. There was an upward trend in the RER following 
SX treatment, which may partly explain the increases in 
ventilation, and further studies of the exercise metabolic 
changes following high-dose SX may be warranted. How- 
ever, the changes in ventilation did not affect the exer- 
cise to,, or significantly alter the @FO, suggesting 
ventilatory efficiency was unchanged. 
Our main aim was to investigate the cardiorespiratory 
response to submaximal exercise. A number of studies have 
examined the effects of long-acting inhaled /?,-agonists on 
maximal performance and oxygen consumption ( kOZman) 
and demonstrated no significant effects (9-12). In a study of 
EXERCISE AND ASTHMA 1057 
eight asthmatic men a single 5Opg dose of salmeterol was 
found not to alter the cardiorespiratory, haemodynamic or 
subjective responses to progressive, maximal exercise, or 
affect endurance capacity (9). Studies on non-asthmatic 
athletes using short-term (single-dose) salmeterol treatment 
have demonstrated no significant effects on short-term 
power output (10,l l), or on a range of cardiorespiratory 
measurements including PO,, tin and HR during submaxi- 
mal treadmill running (at 50-90% of kOZmax) or on running 
time to exhaustion (12). Many sporting activities, team 
games and competitions involve exertion at submaximal 
levels over prolonged periods of time and are more akin to 
tests of endurance capacity. Treatments which offer pro- 
longed control of symptoms are preferable in such circum- 
stances. In this study we have examined the treatment 
effects on submaximal exercise and found no significant 
changes in the 0, cost, or the heart rate response, compared 
to the pretreatment values. 
There is some evidence that controlled release oral sal- 
butamol increases muscle strength with prolonged use (13). 
Systemic P,-agonists are classed as anabolic agents and 
remain prohibited by the International Olympic Committee 
(1). We did not measure muscle strength, however, any 
anabolic effects of systemic salbutamol are unlikely to be 
manifest after the short pretreatment period employed in 
this study. The use of the short pretreatment period 
( 248 h) may have accounted for the attenuation in the 
postexercise fall in FEV, in 42% of the group. Additionally, 
CR inhibited the postexercise fall in FEV, for two patients 
where SX had failed to show an effect. It is well-recognized 
that side-effects tend to be greater with oral therapy and in 
this study CR produced more finger tremor than SX 
(Fig. 2). However, side-effects were similar for both treat- 
ments reflecting the high inhaled dose of SX employed. 
Most patients reported reducing tremor and ‘shakiness’ 
after the first 36 h of either treatment. For patients with 
problematic EIA, and where other inhaled treatments have 
failed to provide sufficient control, intermittent, short-term 
use of CR may be useful for attenuation of EIA, without 
significant effect on the cardiorespiratory response to 
submaximal exercise. 
In conclusion, although subjects exercised from a higher 
baseline FEV, following treatment, there was no evidence 
that short, pretreatment with either high-dose salmeterol 
or controlled release oral salbutamol modified the cardio- 
respiratory response to submaximal exercise in subjects 
with EIA. 
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